N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.7 NOK 0.52%
Market Cap: 881.7m NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NYKD stock under the Base Case scenario is 3.57 NOK. Compared to the current market price of 2.7 NOK, Nykode Therapeutics ASA is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NYKD Relative Value
Base Case
3.57 NOK
Undervaluation 24%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

9.9
P/S
P/S
Price to Sales
9.9
vs History
84
vs Industry
32
Median 3Y
36
Median 5Y
30.4
Industry
6.8
Forward
194.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-15.3
Median 5Y
-12
Industry
21.9
Forward
-27.7
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-1.5
Industry
19.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-1.6
Industry
23.4
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
87
vs Industry
70
Median 3Y
3.9
Median 5Y
5
Industry
2.4
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
25
Median 3Y
24.6
Median 5Y
19.6
Industry
7.2
Forward
-61.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
0.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.6
vs History
29
vs Industry
20
Median 3Y
-7.5
Median 5Y
-6.1
Industry
3.9
Forward
9.2
More Details
0.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.6
vs History
29
vs Industry
18
Median 3Y
-7.3
Median 5Y
-5.9
Industry
3.8
Forward
7.9
More Details
0.5
EV/OCF
EV/OCF
Enterprise Value to OCF
0.5
vs History
49
vs Industry
25
Median 3Y
-2.8
Median 5Y
0.6
Industry
4.4
More Details
0.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.5
vs History
49
vs Industry
21
Median 3Y
-2.7
Median 5Y
0.6
Industry
3.5
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
27
Median 3Y
36.7
Median 5Y
49.3
Industry
4.4
More Details

Multiples Across Competitors

NYKD Competitors Multiples
Nykode Therapeutics ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Nykode Therapeutics ASA
OSE:NYKD
881.7m NOK 9.9 -2.2 0.6 0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 135 164.2 -166 992.2 -202 781.8 -200 467.8
US
Abbvie Inc
NYSE:ABBV
326.5B USD 5.7 78.6 15 22.2
US
Amgen Inc
NASDAQ:AMGN
147.9B USD 4.3 24.9 13.6 22.4
US
Gilead Sciences Inc
NASDAQ:GILD
135.8B USD 4.7 22.8 9.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.9B USD 10.4 -116.2 24.7 25.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 005.1 -511.6 -557.1 -542.3
AU
CSL Ltd
ASX:CSL
118.5B AUD 5 27.7 17.1 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66.5B USD 4.7 14.8 13.4 15
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.2 -63.8 -57.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38B USD 16.2 -140.9 -629.6 -315.5
P/E Multiple
Earnings Growth PEG
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average P/E: 33.8
Negative Multiple: -2.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 992.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.6
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.8
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.7
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.8
7%
2.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -140.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average EV/EBITDA: 13.5
0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 781.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.6
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
14%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -629.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average EV/EBIT: 17.3
0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 467.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.4
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -542.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
13%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -315.5 N/A N/A

See Also

Summary
NYKD intrinsic value, competitors valuation, and company profile.
DCF Valuation
NYKD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NYKD stock valuation using valuation multiples.
Wall Street Estimates
NYKD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NYKD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 256,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.